Healthcare of Ontario Pension Plan Trust Fund Makes New $3.04 Million Investment in Medpace Holdings, Inc. $MEDP

Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the first quarter, Holdings Channel reports. The firm acquired 6,332 shares of the company’s stock, valued at approximately $3,041,000.

A number of other institutional investors also recently added to or reduced their stakes in MEDP. Renaissance Technologies LLC lifted its position in shares of Medpace by 8.3% during the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after buying an additional 38,760 shares during the period. Public Employees Retirement System of Ohio grew its position in Medpace by 12.1% in the first quarter. Public Employees Retirement System of Ohio now owns 17,968 shares of the company’s stock valued at $8,628,000 after acquiring an additional 1,941 shares during the period. Compound Planning Inc. grew its position in Medpace by 8.2% in the first quarter. Compound Planning Inc. now owns 1,432 shares of the company’s stock valued at $688,000 after acquiring an additional 108 shares during the period. Keebeck Wealth Management raised its stake in Medpace by 9.1% during the first quarter. Keebeck Wealth Management now owns 1,434 shares of the company’s stock worth $689,000 after acquiring an additional 120 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Medpace by 5.5% during the first quarter. Arrowstreet Capital Limited Partnership now owns 395,769 shares of the company’s stock worth $190,044,000 after acquiring an additional 20,736 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Price Performance

MEDP stock opened at $578.30 on Friday. The company has a 50 day moving average price of $504.72 and a 200 day moving average price of $493.19. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The stock has a market capitalization of $16.14 billion, a PE ratio of 33.90, a price-to-earnings-growth ratio of 2.61 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period last year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on MEDP. Barclays set a $600.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. TD Cowen lifted their price target on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a report on Friday, July 24th. Mizuho boosted their price target on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Finally, Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and upped their price objective for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and an average price target of $584.18.

Insider Activity at Medpace

In related news, CEO August J. Troendle sold 3,728 shares of Medpace stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $600.85, for a total value of $2,239,968.80. Following the completion of the sale, the chief executive officer directly owned 642,456 shares in the company, valued at $386,019,687.60. This trade represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 31,087 shares of company stock worth $16,203,054 over the last 90 days. Insiders own 20.50% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.